Device Trial Radar · NCT04601155
Transition of Renal Patients Using AlloSure Into Community Kidney Care
Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Nov 19, 2020
Primary completion
Mar 24, 2023
Study completion Oct 6, 2023
Sponsor
- Lead sponsor
- CareDxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 23, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients undergoing kidney transplantation alone (either de-novo or re-transplant) at a participating hospital are routinely surveyed with interval blood tests as part of standard post-operative care through outpatient consultation. These tests include serum creatinine, blood sugar as well as DSA testing at various intervals. The ability to screen patients to better identify those who may be at risk of developing an adverse event using AlloSure cfDNA is likely to be advantageous, with the potential to improve graft survival and outcomes for transplant patients. The addition of AlloSure to the interventional group will be the focus of this study. Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years.Participants will attend outpatient visits/follow-up visits as part of their standard care, these will include appointments where they will have blood tests taken as part of post-transplant surveillance. For AlloSure cfDNA and DSA, blood will be taken quarterly.
Conditions
- Kidney Transplant Rejection
Interventions
AlloSureDevice
AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Superior allograft survivalTime frame: 5 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Amicis Research Center
Fairfield, California
The Medical Research Group - Fresno
Fresno, California
Amicis Research Center
Granada Hills, California
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.